How ELREXFIO works
ELREXFIO is a type of treatment called a BCMA-directed bispecific antibody, also known as a bispecific. It destroys cancer cells by binding to both CD3, a protein found on the surface of T cells, and BCMA, a protein found on the surface of B cells.
ELREXFIO binds to myeloma cells and T cells. ELREXFIO activates those T cells to help destroy myeloma cells
Tap on the labels below to learn more.
T cell Fighter cell
ELREXFIO binds to the CD3 protein found on the surface of T cells. This is a type of white blood cell that can act as a weapon against myeloma cells and other cells.
Myeloma cell Cancer cell
ELREXFIO is designed to bind to BCMA, a protein that is overexpressed on the surface of myeloma cells. BCMA can be found on other B cells, too.
CD3
BCMA
ELREXFIO
This dual binding process activates T cells to target and destroy myeloma cells with BCMA on their surface. It may also harm a type of normal antibody-producing cell.

